4 unknown. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Unknown 4 |
| Phase 2 | 1 | Unknown 1 |
Follow Cryptococcosis: new trials by email Literature Review of Cryptococcosis trials Research Report on Cryptococcosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3 MAT2203, Amphotericin B - Cryptococcal Meningitis | Phase 3 | Unknown | Matinas BioPharma Nanotechnologies, Inc. | 270 | 2023-01-01 | 2022-09-15 |
| AmB Dose for Cryptococcal Meningitis Amphotericin B, Flucytosine - Cryptococcal Meningitis, HIV Infections | Phase 3 | Unknown | Shanghai Public Health Clinical Center | 40 | 2020-01-02 | 2019-10-29 |
| Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa Fluconazole, Flucytosine, lumbar punctures - Cryptococcal Meningitis, HIV | Phase 2 / Phase 3 | Unknown | ANRS, Emerging Infectious Diseases | 41 | 2012-05-01 | 2016-07-12 |
| Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis SPK-843 - Cryptococcosis or Aspergillosis Infections | Phase 3 | Unknown | Proaparts srl | 10 | 2010-05-01 | 2011-06-08 |
Meningitis, Cryptococcal (3) · HIV Infections (2)
Bacterial Infections and Mycoses (4) · Infections (4) · Mycoses (4) · Central Nervous System Diseases (3) · Central Nervous System Fungal Infections (3) · Central Nervous System Infections (3) · Meningitis (3) · Meningitis, Fungal (3) · Nervous System Diseases (3) · Neuroinflammatory Diseases (3) · Blood-Borne Infections (2) · Communicable Diseases (2) · Genital Diseases (2) · Immune System Diseases (2)
Amphotericin B (2) · Flucytosine (2) · Antiretroviral Therapy, Highly Active (1) · Fluconazole (1) · SPA S 843 (1) · Spinal Puncture (1)
ANRS, Emerging Infectious Diseases (1) · Matinas BioPharma Nanotechnologies, Inc. (1) · Proaparts srl (1) · Shanghai Public Health Clinical Center (1)
Burundi (1) · China (1) · Côte d’Ivoire (1) · Italy (1)
David B Meya, MBChB (1) · David R Boulware, MD (1) · Francesco Blasi, MD (1) · Luigi Allegra, Ph.D. (1) · Olivier Bouchaud, PhD (1)